back to webinars

Driving Scientific Breakthroughs with Advanced Assay Development

date

June 26, 2024

time & location

11:00 AM ET, Virtual

REGISTER NOW

Join us for an informative webinar that delves into the cutting-edge capabilities of Quanterix’s Accelerator Laboratory. As a leader in ultra-sensitive immunoassays, Quanterix offers an extensive portfolio of biomarker tests across neurology, inflammation, oncology, and infectious diseases. This webinar is your gateway to understanding how our comprehensive services can streamline your research and clinical trials and drive your scientific breakthroughs. 

Quanterix’s Accelerator Laboratory stands as your one-stop-shop for biomarker assay development, providing robust support from initial antibody screening to final assay validation. Our services are tailored to meet your specific needs, whether it’s developing a custom assay, optimizing existing protocols, or validating analytical performance according to CLSI guidelines. Our state-of-the-art kit production capabilities also ensure seamless support for your clinical trial testing programs. 

We are thrilled to have Dr. Matthew C. Havrda, Associate Professor at Dartmouth’s Geisel School of Medicine, share his exciting research on neuroinflammation in Parkinson’s disease (PD). Dr. Havrda’s work, in collaboration with Quanterix and the Michael J. Fox Foundation, has led to the development of highly sensitive assays for inflammasome-related proteins. His insights will illuminate how these advanced assays can detect inflammasome activity in patient biofluids, providing a critical tool for stratifying and treating patients based on inflammatory pathology. 

Webinar Highlights: 

  • Discover the full spectrum of services offered by Quanterix’s Accelerator Laboratory, from custom assay development to kit production for clinical trials. 
  • Learn how our ultra-sensitive immunoassays can elevate your research in neurology, inflammation, oncology, and infectious diseases. 
  • Gain valuable insights from Dr. Matthew C. Havrda on the role of the NLRP3 inflammasome in neurodegenerative diseases and the innovative assays developed through our collaboration. 

Don’t miss this opportunity to transform your research with the power of ultra-sensitive biomarker testing. Register now to secure your spot.